The antimicrobial peptide LL37 binds to DNA and triggers an immune signaling cascade that recruits T cells to destroy melanocytes, revealing a key mechanism in vitiligo progression.
New mechanistic pathway identifiedLL37-DNA complexes activate TLR9-MyD88 signaling in keratinocytes, triggering chemokine release that recruits the CD8+ T cells responsible for melanocyte destruction in vitiligo.
What the researchers found
The antimicrobial peptide LL37 was found at elevated levels in vitiligo patients' blood and skin lesions. When keratinocytes (skin cells) were exposed to oxidative stress (H2O2), they released LL37, which then bound to DNA forming LL37-DNA complexes. These complexes activated the TLR9-MyD88 signaling pathway in keratinocytes, increasing secretion of chemokines CXCL9, CXCL10, and CXCL16, which in turn attracted CD8+ T cells — the immune cells that destroy melanocytes in vitiligo.
This establishes a mechanistic pathway: oxidative stress → LL37 release → DNA binding → TLR9 signaling → immune cell recruitment → melanocyte destruction.
Why it matters
Vitiligo affects millions of people worldwide, and understanding what triggers the immune system to attack pigment-producing cells is essential for developing targeted treatments. By identifying LL37 as a key early player in this autoimmune cascade, this study reveals a potential therapeutic target — blocking LL37 or its downstream signaling could potentially slow or prevent vitiligo progression.
How the study worked
Researchers measured LL37 levels in serum and skin lesions from vitiligo patients. They then used cell culture experiments to show that oxidative stress (H2O2) causes keratinocytes to release LL37, that LL37-DNA complexes activate TLR9-MyD88 signaling, and that the resulting chemokine secretion drives CD8+ T cell migration toward melanocytes.
Who was studied
Vitiligo patient serum and skin lesion samples; cultured human keratinocytes and CD8+ T cells
What this study cannot tell us
This is primarily a cell culture study supplemented with patient tissue analysis. The mechanistic pathway was demonstrated in vitro and may not fully capture the complexity of vitiligo progression in living patients. No therapeutic intervention was tested. The study does not quantify the exact contribution of LL37 relative to other inflammatory factors in vitiligo.
How to read the evidence
This is a mechanistic study combining patient tissue analysis with in vitro cell experiments. It identifies a plausible biological pathway but does not test a therapeutic intervention or include a clinical trial component.
When this study was published
Published in 2025, this is a recent study contributing to the evolving understanding of autoimmune mechanisms in vitiligo.
The bigger picture
LL37 has been implicated in several autoimmune conditions including psoriasis and lupus. This study extends its role to vitiligo, suggesting that this peptide may be a common driver of autoimmune skin diseases. As LL37-targeted therapies are being explored for other conditions, these findings could accelerate their application to vitiligo as well.
Questions still open
- Could blocking LL37 or TLR9 signaling slow or stop vitiligo progression in patients?
- Is LL37 a useful biomarker for predicting vitiligo flares or progression?
- How does the LL37-driven pathway interact with other known vitiligo triggers like stress and UV exposure?
Common questions
What is LL37 and why is it important in vitiligo?
Could this discovery lead to new vitiligo treatments?
Read the original research
LL37-DNA Complex Drives Vitiligo Progression Through TLR9-MyD88 Signaling Pathways.
Pigment cell & melanoma research, 38(1), e13202
Citation
Wang, Jingying; Mao, Hanxiao; Liu, Rulan; Zeng, Ziyuan; Xie, Lvsha; Yang, Yan; He, Yuanmin. (2025). LL37-DNA Complex Drives Vitiligo Progression Through TLR9-MyD88 Signaling Pathways.. Pigment cell & melanoma research, 38(1), e13202. https://doi.org/10.1111/pcmr.13202